Shafrin: ICER Tackling ‘Pressing Issue’ With Value-Over-Time Reports

from tHEORetically Speaking: The HealthEconomics.Com Blog at on February 28, 2019 at 02:32PM

The Institute for Clinical and Economic Review’s (ICER) decision to do reports on a drug’s value over time is one that “addresses a pressing issue,” according to Jason Shafrin, a health care economist.

Value and estimated value are dynamic variables that are influenced by a range of factors, including new evidence.

“The value of a treatment changes over time based on the evidence available about its benefits, risks, and costs,” Shafrin said during an interview with PharmaLive. “In fact, Dana Goldman and others have proposed a three-part pricing model, where drug prices start out relatively low and increase over time as uncertainty resolves, and then fall after patent expiration.”

Click here to read Shafrin’s commentary.